Browse News
Filter News
Found 3,298 articles
-
Pharmacogenomics Market Size Worth USD 11.97 Billion by 2027
8/17/2022
The global Pharmacogenomics Market is expected to reach USD 11.97 Billion by 2027, according to a new report by Emergen Research.
-
Merck and Orna will explore various therapeutic and vaccine programs in a collaboration worth a potential $3.5 billion.
-
Genprex Announces U.S. Patent for REQORSA™ Immunogene Therapy in Combination with Immune Checkpoint Inhibitors to Treat Cancers
8/16/2022
Genprex, Inc. today announced that the United States Patent and Trademark Office (USPTO) has granted Genprex U.S. Patent No: 11,278,592 B2.
-
BioLineRx Reports Second Quarter 2022 Financial Results and Provides Corporate Update
8/16/2022
BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a pre-commercial-stage biopharmaceutical company focused on oncology, today reports its financial results for the second quarter ended June 30, 2022 and provides a corporate update.
-
Novartis released results from the Phase III CANOPY-A trial, showing that its canakinumab candidate failed to meet its primary efficacy endpoint in adult NSCLC patients.
-
As the biotech world awaits the announcement of Merck’s anticipated buyout of Seagen, an arbitrator came down on the side of Daiichi Sankyo in a patent battle against the Seattle-based biotech.
-
Amgen announced two lung cancer studies with mixed results, Innovent dosed the first patient in a Phase I diabetic macular edema study and HUTCHMED hit the primary endpoint in colorectal cancer.
-
Vaccinex Reports Second Quarter 2022 Results and Provides Corporate Update; Excellent Progress in Pepinemab Clinical Programs
8/15/2022
Vaccinex, Inc. today announced financial results for the second quarter ended June 30, 2022 and provided a corporate update on key events since April, 2022 (the last 5 months).
-
Genprex Announces Safety Review Committee Approves Dose Escalation in Acclaim-1 Phase 1/2 Trial of REQORSA™ in Combination with Tagrisso® in Non-Small Cell Lung Cancer
8/15/2022
Genprex, Inc. today announced that the Safety Review Committee (SRC) has approved continuation of the Acclaim-1 Phase 1/2 clinical trial of REQORSA™ in combination with Tagrisso® (osimertinib) to treat late-stage non-small cell lung cancer (NSCLC) following a review of the first cohort of patients in the Phase 1 portion of the trial.
-
Galectin Therapeutics Reports Financial Results for the Quarter Ended June 30, 2022 and Provides Business Update
8/15/2022
Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the three months ended June 30, 2022.
-
F-star Therapeutics Reports Second Quarter 2022 Financial Results and Corporate Highlights
8/11/2022
F-star Therapeutics, Inc. today announced second quarter 2022 financial results and corporate highlights.
-
Werewolf Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Highlights
8/11/2022
Werewolf Therapeutics, Inc. today provided a business update and reported financial results for the second quarter ended June 30, 2022.
-
ALX Oncology Announces First Patient Dosed in Phase 2 Investigator-Sponsored Trial of Evorpacept in Combination with Cetuximab and Pembrolizumab in Patients with Advanced Colorectal Cancer
8/11/2022
ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO), today announced the initiation of a Phase 2 investigator-sponsored study of evorpacept, a next generation CD47 blocker, in combination with ERBITUX® (cetuximab) and KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy, in patients with refractory microsatellite stable metastatic colorectal cancer (“mCRC”) who have progressed on at least two lines of systemic therapy.
-
Roche receives FDA approval for VENTANA MMR RxDx Panel to identify dMMR solid tumour patients and pMMR endometrial cancer patients eligible for KEYTRUDA
8/11/2022
Roche announced US Food and Drug Administration approval of a label expansion for the VENTANA MMR RxDx Panel.
-
IMV Inc. Announces Second Quarter 2022 Financial and Operational Results
8/11/2022
IMV Inc. today announced its financial and operational results and provided an update for the second quarter ended June 30, 2022.
-
IO Biotech Announces Second Quarter Results for 2022
8/11/2022
IO Biotech, a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies based on its T-win® technology platform, announced financial results for the quarter ending June 30, 2022.
-
SELLAS Life Sciences Provides Business Update and Reports Second Quarter 2022 Financial Results
8/11/2022
SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, provided a business update and reported its financial results for the quarter ended June 30, 2022.
-
Allarity Therapeutics (NASDAQ: ALLR): Diamond in the Rough
8/11/2022
Allarity Therapeutics, Inc. is a clinical stage oncology therapeutics company founded in Denmark in 2004 by Chief Scientific Officer Steen Knudsen, Ph.D.
-
BioLineRx to Report Second Quarter 2022 Results on August 16, 2022
8/11/2022
BioLineRx Ltd. announced today it will release its unaudited financial results for the quarter ended June 30, 2022 on Tuesday, August 16, 2022, before the US markets open.
-
Cancer Monoclonal Antibodies Market Size, Trends, Growth | Report 2022-2030
8/11/2022
The global cancer monoclonal antibodies market was surpassed at USD 62.2 billion in 2021 and is expected to hit around USD 159.96 billion by 2030, growing at a CAGR of 11.07% from 2022 to 2030